US 12,391,768 B2
Antibodies to ticagrelor and methods of use
Andrew Buchanan, Cambridge (GB); Sven Nylander, Sodertalje (SE); Mark Penney, Cambridge (GB); Philip Newton, Cambridge (GB); Feenagh Keyes, Cambridge (GB); and Tord Inghardt, Sodertalje (SE)
Assigned to Medimmune Limited, Cambridge (GB)
Filed by MEDIMMUNE LIMITED, Cambridge (GB)
Filed on Aug. 17, 2023, as Appl. No. 18/451,751.
Application 18/451,751 is a division of application No. 17/176,624, filed on Feb. 16, 2021, granted, now 11,773,186.
Application 17/176,624 is a division of application No. 16/035,954, filed on Jul. 16, 2018, granted, now 10,954,308, issued on Mar. 23, 2021.
Application 16/035,954 is a division of application No. 15/966,313, filed on Apr. 30, 2018, abandoned.
Application 15/966,313 is a continuation of application No. 14/871,111, filed on Sep. 30, 2015, granted, now 9,982,061, issued on May 29, 2018.
Claims priority of provisional application 62/114,931, filed on Feb. 11, 2015.
Claims priority of provisional application 62/058,458, filed on Oct. 1, 2014.
Prior Publication US 2024/0101712 A1, Mar. 28, 2024
Int. Cl. C07H 21/04 (2006.01); C07D 487/04 (2006.01); C07K 16/44 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/44 (2013.01) [C07D 487/04 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 17 Claims
 
1. Nucleic acid encoding an antibody or a fragment thereof comprising complementarity-determining region (CDR) combinations selected from the group consisting of:
SEQ ID NO:53 (VH CDR1), SEQ ID NO:54 (VH CDR2), SEQ ID NO:55 (VH CDR3), SEQ ID NO:58 (VL CDR1), SEQ ID NO:59 (VL CDR2), and SEQ ID NO:60 (VL CDR3);
SEQ ID NO:63 (VH CDR1), SEQ ID NO:64 (VH CDR2), SEQ ID NO:65 (VH CDR3), SEQ ID NO:68 (VL CDR1), SEQ ID NO:69 (VL CDR2), and SEQ ID NO:70 (VL CDR3); and
SEQ ID NO:73 (VH CDR1), SEQ ID NO:74 (VH CDR2), SEQ ID NO:75 (VH CDR3), SEQ ID NO:78 (VL CDR1), SEQ ID NO:79 (VL CDR2), and SEQ ID NO:80 (VL CDR3);
wherein the antibody or fragment thereof binds to ticagrelor ((1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol) or a metabolite or derivative thereof.